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ABSTRACT 
Objective: The study was aimed to find out the correlation between cyclosporine blood concentrations and (Clusters of Differentiation 4) CD4 T-
helper cell count (percentage) in order to use the latter parameter as an alternative marker for cyclosporine dosing. Besides, the study was also 
aimed to find out the optimum dosing strategy for Iraqi patients requiring cyclosporine therapy in Iraqi hospitals using TDM approach.  
Methods: One hundred and twenty subjects participated in the study. The subjects are involved two groups; group A was 80 patients (53 males and 
27 females) using cyclosporine twice daily (Sandimmune
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® oral solution containing cyclosporine 100 mg/ml) and they had kidney transplantation 
for more than one year. The ages of the patients were 15-45 y (mean±SD =31.962±8.8207); and. Group B included 40 healthy control subjects (24 
males and 16 females) with ages of 15-45 y (mean±SD =31.666±8.1606). According to the condition and the need of the patients, they were 
administered cyclosporine dose range of 1-10 mg/kg/d. Ten ml blood samples were withdrawn from each patient after fasting for about 12 h for 
monitoring trough/minimum blood concentration (C0) of cyclosporine and for determination of (Clusters of Differentiation 4) CD4 T-helper cells 
count at C0. Other 10 ml of blood was then withdrawn after 2 h of cyclosporine administration to be used for monitoring maximum/peak 
cyclosporine blood cyclosporine (Cmax) after 2 h of drug intake (C2) and for determination of (Clusters of Differentiation 4) CD4 T-helper cells 
count at C2. Five ml of blood samples were withdrawn from each control subject for determination of (Clusters of Differentiation 4) CD4 T-helper 
cells count.  
Results: Good correlations were found between cyclosporine dose administered to each patient and the resulted C0 and C2. The majority of 
patients (66 patients=82.5%) had C0 of 150-200 ng/ml and C2 of 700-900 ng/ml, which are within the therapeutic range. The range of cyclosporine 
doses that produce therapeutic C0 and C2 was 4.1-9 mg/kg/d. The mean total lymphocyte count and percentage decreased significantly in all 
patients compared to the control subjects (1.26±0.60 vs.1.98±0.66 e3
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/uL) and (19.92±13.77 vs. 28.88±10.22), respectively. A similar trend was 
found for the total lymphocyte count and percentage of patients with cyclosporine C0, and C2 within the therapeutic range (66 patients) compared 
to the control subjects (1.34±0.57 vs. 1.98±0.66) and (18.98±10.93 vs. 28.88±10.22), respectively. Good negative correlations were found between 
lymphocyte count and percentage versus C0 for all patients and for patients with C0 within the therapeutic range. Similarly, good negative 
correlations were found between lymphocyte count and percentage versus C2 for all patients and for patients with C2 within the therapeutic range. 
The (Clusters of Differentiation 4) CD4 T-helper cell percentage at C0 decreased significantly in all patients and patients with cyclosporine blood 
concentrations within the therapeutic range (66 patients) compared to the control subjects (24.33±10.31 vs. 35.83±9.11) and (25.50±2.44 vs. 
35.83±9.11), respectively. Similarly, (Clusters of Differentiation 4) CD4 T-helper cell percentage at C2 decreased significantly in all patients and 
patients with cyclosporine blood concentrations within the therapeutic range compared to the control subjects (22.60±9.28 vs. 35.83±9.11) and 
(21.50±2.16 vs. 35.83±9.11), respectively. The range of (Clusters of Differentiation 4) CD4 T-helper cell percentages at C0 for patients with 
cyclosporine blood levels above the therapeutic concentrations was 21.65-23.43; for patients with cyclosporine blood levels within the therapeutic 
concentrations, the range was 23.70-29.00; and for patients with cyclosporine blood levels below the therapeutic concentrations, the range was 
29.80-34.60. Good negative correlations were found between (Clusters of Differentiation 4) CD4 T-helper cell percentage and C0 for all patients and 
for patients with blood concentrations of cyclosporine within the therapeutic range. The (Clusters of Differentiation 4) CD4 T-helper cell percentage 
range at C2 for patients with cyclosporine blood levels above the therapeutic concentrations was 13.40-18.20; for patients with cyclosporine blood 
levels within the therapeutic concentrations, the range was 18.50-22.23; and for patients with cyclosporine blood levels below the therapeutic 
concentrations, the range was 22.76-24.42. Identically, good negative correlations were found between (Clusters of Differentiation 4) CD4 T-helper 
cell percentage and C2 for all patients and for patients with blood concentrations of cyclosporine within the therapeutic range. For patients with 
cyclosporine blood levels above therapeutic concentrations; the minimum percentage of (Clusters of Differentiation 4) CD4 T-helper cell at C2 was 
13.40, whereas, the maximum percentage of (Clusters of Differentiation 4) CD4 T-helper cell at C0 was 20.23. For patients with cyclosporine blood 
levels within therapeutic concentrations; the minimum percentage of (Clusters of Differentiation 4) CD4 T-helper cell at C2 was 18.50, whereas, the 
maximum percentage of (Clusters of Differentiation 4) CD4 T-helper cell at C0 was 29.00. For patients with cyclosporine blood levels below 
therapeutic concentrations; the minimum percentage of (Clusters of Differentiation 4) CD4 T-helper cell at C2 was 23.40, whereas, the maximum 
percentage of (Clusters of Differentiation 4) CD4 T-helper cell at C0 was 34.60.  
Conclusion: Good negative (reciprocal) correlations were demonstrated between cyclosporine blood concentrations at C0 and C2 versus The 
percentage of (Clusters of Differentiation 4) CD4 T-helper cell. Therefore, the percentage of (Clusters of Differentiation 4) CD4 T-helper cell may be 
used as an alternative or surrogate marker for optimum cyclosporine dosing than the traditional dosing strategy using TDM, since the former 
approach is direct for reflecting drug safety and efficacy, beside, it is the affordable, fast and simple approach. The range of cyclosporine doses that 
produce therapeutic C0 and C2 in Iraqi kidney transplant patients was 4.1-9 mg/kg/d. 
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INTRODUCTION 
Cyclosporine also called cyclosporine A and Ciclosporin (often 
shortened to CsA). Cyclosporine is indicated for the prophylaxis of 
organ rejection in heart, liver and kidney allogeneic transplants. 
Besides, cyclosporine may also be indicated for patients who were 
previously treated with other immunosuppressive agents. Although 
many cells may participate in the process of kidney transplant 
rejection, only T lymphocytes seem to be absolutely required [1, 2]. 
T-lymphocytes cells express either the CD4 or the CD8 surface 
glycoprotein but not both [3, 4]. The main event in both the initiation 
and coordination of the rejection responses T-cell activation, 
moderated by interleukin-2, a cytokine. Interleukin-2 is produced by 
CD4 cells and to a lesser extent by CD8 cells [5, 6]. 
There are so many reasons, which make cyclosporine a 
distinguished example of drugs, which require drug monitoring, and 
individualization for optimal therapy to the patients. These reasons 
include; narrow therapeutic index of the drug (the drug causes 
irreversible kidney damage when given above therapeutic dose, and 
on the other extreme cause rejection of transplanted organ when 
given below therapeutic dose), the existence of number of drug 
interactions that affect cyclosporine levels, variable inter-and intra-
patients pharmacokinetics, in addition to, the differences in the drug 
pharmacokinetics between formulas and manufacturers [7, 8]. 
Many studies demonstrated the impact of cyclosporine on reducing 
CD4-T helper cells, which are responsible for immunosuppression 
caused by cyclosporine in renal transplant patients [9-12]. However, 
up to date, there is no published data which show the correlation 
between cyclosporine dose administered and the resulting trough and 
maximum concentrations of the drug, in one hand, and the percent of 
the reduction in CD4-T helper cells, on the other hand. Therefore, the 
present investigation was aimed to find out the correlation between 
cyclosporine levels and the percent of the reduction in CD4-T helper 
cells, since the latter approach is considered as a direct marker, which 
reflects cyclosporine safety and efficacy. Besides, measuring CD4-T 
helper cells is the affordable, simple, easy and fast approach. The other 
objective of the current study was to find out the therapeutic dose 
range of cyclosporine, which produces therapeutic blood levels in Iraqi 
kidney transplant patients. 
MATERIALS AND METHODS 
Study design 
The study was conducted in TDM Center, Baghdad Teaching 
Hospital, Medical City/Baghdad/Iraq. Eighty renal transplant 
patients (53 males and 27 females) who have been using 
cyclosporine (Sandimmune® oral solution containing cyclosporine 
100 mg/ml) for at least one year were involved in the study. These 
patients were classified as group A. Beside, 40 healthy subjects (24 
male and 16 female) were also included in the study as control 
subjects, and these subjects were classified as group B. All patients 
and control subjects gave informed consent for participation before 
the initiation of the study. 
Blood sampling from the patients 
After fasting for about 12 h, few minutes before administration of the 
next cyclosporine dose; 10 ml of blood sample was withdrawn from each 
patient and transferred immediately to tube containing EDTA to be used 
for monitoring the trough/minimum concentration (C0) of cyclosporine, 
and for determination CD4 T-helper cells count at C0. Other 10 ml of 
blood was then withdrawn after 2 h of cyclosporine administration to be 
used for monitoring cyclosporine after 2 h (C2) of cyclosporine 
administration (which represent the peak or maximum level), and for 
determination CD4 T-helper cells count at C2. 
Blood sampling from the control subjects 
Five ml blood was withdrawn from each healthy control subject 
after fasting for about 12 h to be used for determination CD4 T-
helper cells count.  
Determination of cyclosporine blood concentrations in the patients 
Cyclosporine blood concentrations were determined by Abbott 
AxSYM system. The AxSYM assay is a fluorescence polarization 
immunoassay (FPIA) in vitro reagent system used for quantitative 
measurement of cyclosporine in human whole blood as an aid in the 
management of organ transplantation [13, 14]. 
Determination of CD4 T-helper cells percentage 
The percentage of CD4 T-helper cells was measured by Partec GMBH 
flow cytometry [15, 16]. 
Statistical analysis of data 
Statistical analysis of the results obtained in this study included; 
mean±standard deviation (SD), analysis of variance (ANOVA) single 
factor, and correlation coefficient (r). The results of the analysis with 
P value<0.05 were considered significant. Statistical analysis and 
graphs were carried out by Microsoft Office Excel 2007 software.  
RESULTS AND DISCUSSION 
Doses of cyclosporine taken by the patients 
Table 1 shows the number and the percentage of patients versus 
cyclosporine doses taken by the patients. 
  
Table 1: Cyclosporine doses taken versus number and percentage of patients 
Cyclosporine dose mg/kg/d Number of patients Percentage of patients 
1-2 mg/kg/d 1 1.25% 
2.1-3 mg/kg/d 3 3.75% 
3.1-4 mg/kg/d 5 6.25% 
4.1-5 mg/kg/d 11 13.75 % 
5.1-6 mg/kg/d 31 38.75 % 
6.1-7 mg/kg/d 9 11.25 % 
7.1-8 mg/kg/d 7 8.75 % 
8.1-9 mg/kg/d 8 10% 
9.1-10 mg/kg/d 5 6.25 % 
Total  80 100% 
 
Blood levels of cyclosporine in the patients 
Table 2 shows cyclosporine minima (trough) blood 
concentrations (C0) and the maximum concentration after 2 h of 
drug intake (C2). 
For C0; the level was less than 150 ng/ml in 9 patients (11.25%), 
more than 200 ng/ml in 5 patients (6.25%), and within the 
therapeutic range of 150-200 ng/ml in 66 patients (82.5%). C2; the 
level was less than 700 ng/ml in 9 patients (11.25%), more than 900 
ng/ml in 5 patients (6.25%), and within the therapeutic range of 
700-900 ng/ml in 66 patients (82.5%). 
Relationship between cyclosporine dose and concentrations 
Fig. 1 demonstrates the relationship between the doses taken by the 
patients and C0. Fig. 2 demonstrates the relationship between the 
doses taken by the patients and C2. In both situations, a good 
correlation was found between doses taken and the corresponding 
C0 (r=0.90199, fig. 1), and C2 (r=0.91415, fig. 2). 
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Lymphocytes count versus blood levels of cyclosporine for the 
patients versus the control subjects 
Table 3 indicates that the mean total lymphocyte count decreased 
significantly in all the patients compared to control subjects 
(1.26±0.60 vs. 1.98±0.66 e3/uL). A similar trend was found for total 
lymphocyte count in patients with cyclosporine C0, and C2 within 
the therapeutic range (66 patients) compared to control subjects 
(1.34±0.57 vs. 1.98±0.66). 
 
Fig. 1: Relationship between cyclosporine doses and blood 
trough concentrations (C0) 
 
Fig. 2: Relationship between cyclosporine doses and blood 
concentrations after 2 h of drug intake (C2) 
 
The correlation between lymphocyte count and C0 for all patients 
and for patients with C0 within therapeutic range is presented in fig. 
4A and 4B, respectively. In both situations, the good negative 
correlation was found between lymphocyte count and C0 with 
r=0.93295 (fig. 3.25A), and r=0.97361(fig. 3.25B). 
 
Table 2: Sampling time and blood levels of cyclosporine versus number of patients. Total number of patients=80 
Sampling time Blood concentration (ng/ml) Number of patients Percentage of patients 






150-200 66 A 82.5% 






700-900 66 B 82.5% 
A: Therapeutic minimum concentration (C0) of cyclosporine, B: Maximum Therapeutic concentration (C2) after 2 h of drug intake 
 
Table 3: Lymphocyte counts in control subjects versus the patient using cyclosporine 
Parameter Group N Mean ±SD P-value 
Lymphocytes count (e3/uL)  All patients 80 1.26 0.60 0.02066* 
Control 40 1.98 0.66  
Lymphocytes count (e3/uL) Patients with therapeutic cyclosporine concentrations (C0 and C2) 66 1.34 0.57 0.03189* 









Fig. 3B: Correlation between lymphocyte count and C0 for 
patients with therapeutic blood concentrations of cyclosporine 
 




Fig. 4B: Correlation between lymphocyte count and C0 for 
patients with therapeutic blood concentrations of cyclosporine 
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Fig. 5B: Correlation between lymphocyte count and C2 for 
patients with therapeutic blood concentrations of cyclosporine 
Lymphocytes percentage versus blood levels of cyclosporine for 
the patients versus the control subjects  
Table 4 shows that the mean total lymphocyte percentage decreased 
significantly in all patients compared to control subjects (19.92±13.77 vs. 
28.88±10.22 e3
The correlation between lymphocyte percentage and C2 for all 
patients and for patients with cyclosporine blood concentrations 
within the therapeutic range is introduced in fig. 7A and 7B, 
respectively. In both cases good negative correlation observed 
with r= 0.91052 (fig. 7A), and r=0.95185 (fig. 7B). 
/uL). A similar trend was found for lymphocyte 
percentage of patients with cyclosporine blood levels within the 
therapeutic range (66 patients) compared to control subjects 
(18.98±10.93 vs. 28.88±10.22). The correlation between lymphocyte 
percentage and C0 for all patients and for patients with cyclosporine 
blood concentrations within the therapeutic range is introduced in fig. 
6A and 6B, respectively. In both cases good negative correlation 
observed with r= 0.93295 (fig. 6A), and r= 0.97361 (fig. 6B). 
Percentage of CD4 T-helper cell at C0 for the patients versus the 
control subjects 
Table 5 demonstrates that CD4 T-helper cell percentage at C0 
decreased significantly in all patients compared to control subjects 
(24.33±10.31 vs. 35.83±9.11). Similar trend was found for CD4 T-
helper cell percentage at C0 in the patients with cyclosporine blood 
concentrations within the therapeutic range (66 patients) compared 
to the control subjects (25.50±2.44 vs. 35.83±9.11). 
 
Table 4: Lymphocyte percentage in the control subjects versus the patients using cyclosporine 
Parameter Group N Mean ±SD P-value 
Lymphocytes %  All patients 80 19.92 13.77 0.03336* 
Control 40 28.88 10.22 
Lymphocytes %  Patients with therapeutic cyclosporine concentrations (C0 and C2) 66 18.98 10.93 0.00732* 








Fig. 6B: Correlation between lymphocyte percentage and C0 








Fig. 7B: Correlation between lymphocyte percentage and C2 
for patients with therapeutic blood concentrations of 
cyclosporine 
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Table 5: Percentage of CD4 T-helper cell at C0 for the control subjects versus the patients using cyclosporine 
Parameter Group N Mean ±SD P-value 
CD4 T-helper % at C0 All patients 80 24.33 10.31 0.00122* 
Control 40 35.83 9.11 
CD4 T-helper % at C0 Patients With therapeutic cyclosporine concentrations 66 25.50 2.44 0.01097* 
Control 40 35.83 9.11 
*Significant difference 
 
Percentage of CD4 T-helper cell at C2 for the patients versus the 
control subjects 
Table 6 denote that CD4 T-helper cell percentage at C2 decreased 
significantly in all the patients compared to control subjects 
(22.60±9.28 vs. 35.83±9.11). A similar trend was found for CD4 T-
helper cell percentage at C2 in patients with cyclosporine blood 
concentrations within the therapeutic range compared to the control 
subjects (21.50±2.16 vs. 35.83±9.11). 
Range of CD4 T-helper cell percentage at C0 for all patients 
Table 7 show that the range of CD4 T-helper cell percentage at C0 for 
patients with cyclosporine blood levels above the therapeutic 
concentrations was 21.65-23.43 with mean±SD (22.67±0.81); for 
patients with cyclosporine blood levels within the therapeutic 
concentrations, the range was 23.70-29.00 with mean±SD (25.52±2.44); 
and for patients with cyclosporine blood levels below the therapeutic 
concentrations, the range was 29.80-34.60 with mean±SD (31.72±1.60). 
 
Table 6: Percentage of CD4 T-helper cell at C2 for the control subjects versus the patients using cyclosporine 
Parameter Group N Mean ±SD P-value 
CD4 T-helper % at C2 All patients 80 22.60 9.28 0.00013* 
Control 40 35.83 9.11 
CD4 T-helper % at C2 Patients with therapeutic cyclosporine concentrations 66 21.50 2.16 0.003432* 
Control 40 35.83 9.11 
*Significant difference 
 
Table 7: Range of CD4 T-helper cell percentage at C0 for all patients, total number of patients=80 
Patients (total 80) Range of CD4% at C0 Mean ±SD 
Patients with cyclosporine blood concentrations above therapeutic range (5 patients only) 21.65-23.43 22.67 0.81 
Patients with cyclosporine blood concentrations within therapeutic range (66 patients) 23.7-29.00  25.52 2.44 
Patients with cyclosporine blood concentrations below therapeutic concentration (9 patients only) 29.8-34.60 31.72 1.60 
 
Since the percentage of CD4 T-helper cell in control subjects was 
35.8, thus a clear reduction in the percentage of CD4 T-helper cell 
occurred when C0 were above and within therapeutic levels. 
However, when C0 were below the therapeutic levels, the reduction 
in the percentage of CD4 T-helper cell was not remarkable. This 
reflects the direct influence of C0 levels on reducing the percentage 
of CD4 T-helper cell and consequently the depression of immunity 
from kidney transplanted patients. The correlation between CD4 T-
helper cell percentage and C0 for all patients is shown in fig. 8A. The 
correlation between CD4 T-helper cell percentage and C0 for 
patients with blood concentrations of cyclosporine within the 
therapeutic range is depicted in fig. 8B. In both situations, good 
negative correlations were found with r=0.97928 (fig. 8A) and 
r=0.9379 (fig. 8B). 
 
Fig. 8A: Correlation between CD4 T-helper cell percentage and 
C0 for all patients 
 
Fig. 8B: Correlation between CD4 T-helper cell percentage and 
C0 for patients with therapeutic blood concentrations of 
cyclosporine 
 
Range of CD4 T-helper cell percentage at C2 for all patients  
Table 8 display that the CD4 T-helper cell percentage range at C2 for 
patients with cyclosporine blood levels above the therapeutic 
concentrations was 13.40-18.20 with mean±SD (16.08±1.96); for 
patients with cyclosporine blood levels within the therapeutic 
concentrations, the range were 18.50-22.23 with mean±SD 
(21.52±2.19); and for patients with cyclosporine blood levels below 
the therapeutic concentrations, the range were 22.76-24.42 with 
mean±SD (23.75±0.66). 
 
Table 8: Range of CD4 T-helper cell percentage at C2 for all patients, N=80 patients 
Patients Range of CD4% at C2 Mean ±SD 
Patients with cyclosporine blood concentrations above therapeutic range (5 patients only) 13.40-18.2 16.08 1.96 
Patients with cyclosporine blood concentrations within therapeutic range (66 patients) 18.5-22.23 21.52 2.19 
Patients with cyclosporine blood concentrations below therapeutic concentrations (9 patients only) 22.76-24.42 23.75 0.66 
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Since the percentage of CD4 T-helper cell in control subjects was 
35.80, thus an apparent reduction in the CD4 T-helper cell occurred 
when C2 were above, within and below the therapeutic levels. 
However, the reduction in the percentage of CD4 T-cell was more 
remarkable when C2 were above and within the therapeutic levels. 
This reflects the direct impact of C2 levels on reducing the 
percentage of CD4 T-helper cell and consequently the depression of 
immunity for kidney transplanted patients. The correlation between 
CD4 T-helper cell percentage and C2 for all patients is shown in fig. 
9A. The correlation between CD4 T-helper cell percentage and C2 for 
patients with blood concentrations of cyclosporine within the 
therapeutic range is illustrated in fig. 9B. In both cases, good 
negative correlations were found with r= 0.99606 (fig. 9A) and r= 
0.98188 (fig. 9B). 
Range of CD4 T-helper cell percentage at C2 to C0 for the patients 
Table 9 demonstrates that, for patients with cyclosporine blood 
levels above therapeutic concentrations; the minimum percentage of 
CD4 T-helper cell at C2 was 13.40, whereas the maximum 
percentage of CD4 T-helper cell at C0 was 20.23. For patients with 
cyclosporine blood levels within therapeutic concentrations; the 
minimum percentage of CD4 T-helper cell at C2 was 18.50, whereas 
the maximum percentage of CD4 T-helper cell at C0 was 29.00. For 
patients with cyclosporine blood levels below therapeutic 
concentrations; the minimum percentage of CD4 T-helper cell at C2 
was 23.40, whereas the maximum percentage of CD4 T-helper cell at 
C0 was 34.60. 
 
Fig. 9A: Correlation between CD4 T-helper cell percentage and 
C2 for all patients 
 
 
Fig. 9B: Correlation between CD4 T-helper cell percentage and 
C2 for patients with therapeutic blood concentrations of 
cyclosporine
 
Table 9: Range of CD4 T-helper cell percentages at C2 to C0 for patients with cyclosporine blood concentrations above, within and below 
therapeutic levels 
Patients Range of CD4 T-helper cell percentage 




CD4 T-helper cell percentage for patients with cyclosporine blood levels above 
therapeutic concentrations 
14.30-20.23 16.44 2.86 
CD4 T-helper cell percentage for patients with cyclosporine blood levels within 
therapeutic concentrations 
18.50-29.00 24.61 3.32 
CD4 T-helper cell percentage for patients with cyclosporine blood levels below 
therapeutic concentrations 
23.40-34.60 28.80 3.76 
 
DISCUSSION  
Dosage of cyclosporine  
The maintenance dose of cyclosporine in renal transplanted patients 
is 5-10 mg/kg/d [13] and therapeutic blood concentrations C0 
range150-200 ng/ml, and C2 range 700-900 ng/ml [14]. 
In the present study, the distribution of the different cyclosporine 
doses; as 1-2 mg/kg/d, 2.1-3 mg/kg/d, 3.1-4 mg/kg/d, 4.1-5 
mg/kg/d, 5.1-6 mg/kg/d, 6.1-7 mg/kg/d, 7.1-8 mg/kg/d, 8.1-9 
mg/kg/d and 9.1-10 mg/kg/d were; 1 (1.25%), 3 (3.75%), 5 
(6.25%), 11 (13.75 %), 31 (38.75 %), 9 (11.25 %), 7 (8.75 %), 8 
(10%) and 5 (6.25 %), respectively. The range of doses that produce 
cyclosporine therapeutic range was 4.1-9 mg/kg/d. Further studies 
on Iraqi kidney transplant patients are needed to support the 
present result. 
Blood levels of cyclosporine 
Dose adjustment of medication is accomplished according to the 
blood levels. A high level can be harmful to the transplanted kidney, 
and a low level may lead to rejection [15]. Patient’s cyclosporine 
levels should often be measured for the rest of their life. In Iraq, 
cyclosporine levels are measured in Baghdad Teaching Hospital/ 
TDM unit in periods depending on the time of transplantation.  
The current findings showed that the number of patients with a 
therapeutic range of cyclosporine (C0=150-200 ng/ml, and C2=700-
900 ng/ml) was 66 (82.5%) who received dose range of 4.1-9 
mg/kg/d. The number of patients with levels above therapeutic 
range (205-250 ng/ml for C0 and 955-1100 ng/ml for C2) was 5 
(6.25 %) who received dose 9.1-10 mg/kg/d of cyclosporine. 
Whereas, the number of patients with levels under the therapeutic 
range (100-148 ng/ml for C0 and 600-693 for C2) was 9 (11.25%) 
who received doses less than 4 mg/kg/d. 
Cyclosporine dose and concentration relationship 
The concept of the therapeutic range in population-based statistical 
approaches, suggesting that most patients who achieve a desired 
therapeutic response commonly occur at specific target 
concentrations. Significant variability in cyclosporine 
pharmacokinetics, the narrow therapeutic index, the dangerous 
adverse effects justify the use of TDM for cyclosporine [16]. 
Although, there is a significant variability in the pharmacokinetics of 
cyclosporine, the present finding showed good correlation between 
doses and blood concentrations at C0 and C2 with r=0.901 and 
r=0.914, respectively. 
Lymphocytes and CD4 T-helper cell 
Cyclosporine causes inhibition of IL-2 and other cytokines 
production throughout a complex formation with cyclophilin that 
inhibits calcineurin leading to diminishing of T-cell activation [17]. 
Cyclosporine cause calcineurin inhibition in T cells that block the 
dephosphorylation and translocation of NFATc then inhibition of 
cytokine production from memory CD4+T cells occur as a 
consequence, the differentiation of naïve CD4+T cells into cytokine-
producing memory CD4+T cells is prevented [18]. 
One measurable effect of low dose of cyclosporine, a significant 
reduction in absolute numbers of CD4+T cell count at weeks 2 and 4 
is observed and this is related to the inhibition of IL-2-induced T cell 
proliferation ability of cyclosporine [19]. 
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Lymphocytes count and blood levels (C0 and C2) of cyclosporine 
for the patients versus the control subjects 
In this study, there was a significant reduction in mean total 
lymphocyte count in all patients (80 patients) compared to the 
control subjects (40 subjects). Besides, a significant reduction in 
total lymphocyte count was recorded in the patients (66 patients) 
with cyclosporine blood levels within the therapeutic range of C0 
and C2 compared to the control subjects. The present investigation 
also demonstrated a good negative correlation between lymphocyte 
count and C0 for all patients with r=0.932 and for patients with C0 
within the therapeutic range with r=0.973. Moreover, good negative 
correlation was observed between the lymphocyte count and C2 for 
all patients with r=0.904 and for patients with C2 within the 
therapeutic range with r=0.939. This reduction in the total 
lymphocyte count is due to the reduction in CD4 T-helper cell count. 
Percentage of CD4 T-helper cell at C0 for the patients versus the 
control subjects 
This study exhibited a significant reduction in CD4 T-helper cell 
percentage at C0 in all patients (80 patients) compared to the control 
subjects (40 subjects). Also, significant reduction in CD4 T-helper cell 
percentage at C0 in the patients with cyclosporine blood levels within 
the therapeutic range (66 patients) compared to the control subjects. 
This is due to inhibition of differentiation of naïve CD4 T cells into 
cytokine-producing memory CD4 T helper cell by cyclosporine. 
Percentage of CD4 T-helper cell at C2 for the patients versus the 
control subjects 
The current investigation elucidated significant reduction in CD4 T-
helper cell percentage at C2 in all patients (80 patients) compared to 
the control subjects (40 subjects). In addition, a significant reduction 
in CD4 T-helper cell percentage at C2 in the patients with 
cyclosporine blood levels within the therapeutic range (66 patients) 
compared to the control subjects. This is due to inhibition of 
differentiation of naïve CD4+T cells into cytokine-producing 
memory CD4+T cells by cyclosporine. 
Range of CD4 T-helper cell percentage at C0 for all patients 
In this study, the range of CD4 T-helper cell percentage at C0 for the 
patients with cyclosporine blood levels above the therapeutic 
concentrations was 21.65-23.43 with mean±SD (22.67±0.81); for 
patients with cyclosporine blood levels within the therapeutic 
concentrations, the range was 23.7-29 with mean±SD (25.52±2.44); 
and for patients with cyclosporine blood levels below the 
therapeutic concentrations, the range was 29.8-34.6 with mean±SD 
(31.72±1.60). Since the percentage of CD4 T-helper cell in control 
subjects was 35.8, thus an apparent diminishing in the percentage of 
CD4 T-helper cell took place when C0 were above and within 
therapeutic levels. However, when C0 were below the therapeutic 
levels, the decline in the percentage of CD4 T-helper cell was not 
noticeable. This indicates the direct effect of C0 levels on diminishing 
the percentage of CD4 T-helper cell and consequently decreasing the 
immunity on kidney transplant patients. 
The present investigation demonstrated a good negative correlation 
between CD4 T-helper cell percentage and C0 for all patients with 
r=0.97928, and the good negative correlation between CD4 T-helper 
cell percentage and C0 for the patients with blood concentrations of 
cyclosporine within the therapeutic range with r=0.9379. 
Range of CD4 T-helper cell percentage at C2 for all patients 
In this study, the range of CD4 T-helper cell percentage at C2 for the 
patients with cyclosporine blood levels above the therapeutic 
concentrations was 13.4-18.2 with mean±SD (16.08±1.96); for 
patients with cyclosporine blood levels within the therapeutic 
concentrations, the range was 18.5-22.23 with mean±SD 
(21.52±2.19); and for patients with cyclosporine blood levels below 
the therapeutic concentrations, the range was 22.76-24.42 with 
mean±SD (23.75±0.66). 
Since the percentage of CD4 T-helper cell in control subjects was 
35.8, thus a clear reduction in the CD4 T-helper cell occurred when 
C2 were above, within and below the therapeutic levels. However, 
the reduction in the percentage of CD4 T-cell was more apparent 
when C2 were above and within the therapeutic levels. This mirror 
the direct impact of C2 levels on decreasing the percentage of CD4 T-
helper cell and consequently leads to decline in the immunity of 
kidney transplanted patients.  
The current study display the good negative correlation between 
CD4 T-helper cell percentage and C2 for all patients with r=0.99606, 
and the good negative correlation between CD4 T-helper cell 
percentage and C0 for the patients with blood concentrations of 
cyclosporine within the therapeutic range with r= 0.98188. 
Range of CD4 T-helper cell percentage at C2 to C0 for the patients 
The present instigation manifest that the patients with cyclosporine 
blood levels above therapeutic concentrations; the minimum 
percentage of CD4 T-helper cell at C2 was 13.40, whereas the 
maximum percentage of CD4 T-helper cell at C0 was 20.23. For 
patients with cyclosporine blood levels within therapeutic 
concentrations; the minimum percentage of CD4 T-helper cell at C2 
was 18.50, whereas the maximum percentage of CD4 T-helper cell at 
C0 was 29.00. For patients with cyclosporine blood levels below 
therapeutic concentrations; the minimum percentage of CD4 T-
helper cell at C2 was 23.40, whereas the maximum percentage of 
CD4 T-helper cell at C0 was 34.60. 
From these results, measurement of CD4 T-helper cell percentage 
could be used as an alternative marker to TDM for dosing 
cyclosporine. According to this approach, the monitoring is based on 
measuring CD4 T-helper cell percentage after 12 h of cyclosporine 
dose administration (trough cyclosporine blood level C0) and the 
range of CD4 T-helper cell percentages should be 23.7-29.00%. The 
second measurement of CD4 T-helper cell percentage should be 
after 2 h of cyclosporine dosage administration (maximum or peak 
cyclosporine blood level C2) and the range should be 18.5-22.23%. 
Hence, the dose administered to the patient should be adjusted to 
produce the above-mentioned ranges of CD4 T-helper cell 
percentage, then this dose can be considered as the optimal dose of 
cyclosporine which should be maintained to the patient; since this 
dose indicate that the patient is maintained within the therapeutic 
blood concentration ranges C0 and C2 of cyclosporine. Accordingly, 
measurement of CD4 T-helper cell percentage can be considered as a 
promising novel alternative/surrogate approach for cyclosporine 
dosing, since monitoring CD4 T-helper cell percentage is the direct, 
simple, fast and affordable approach. 
Limitation of the study 
1. The possibility of Cyclosporine dosage change in stable patients. 
2. Period of the study should take longer to involve larger number of 
patients 
3. Using the new, simple and rapid method for CD4 T–helper cells 
counting method. 
CONCLUSION 
For Iraqi kidney transplant patients using oral cyclosporine twice 
daily, it appeared that there is good negative (reciprocal) correlation 
between cyclosporine blood levels (C0 = trough or minimum level 
after 12 h of drug administration, and C2 = maximum level after 2 h of 
drug intake) and the percentage of CD4 T-helper cell. Since the latter 
parameter is a direct marker which reflects cyclosporine safety and 
efficacy, besides, measuring the percentage of CD4 T-helper cell is 
affordable, simple and fast. Thus, it can be concluded from the current 
study that the percentage of CD4 T-helper cell may be used as a novel 
promising alternative or surrogate marker for optimum cyclosporine 
dosing. Moreover, cyclosporine dose range of 4.1-9 mg/kg/d yields 
therapeutic C0 and C2 in Iraqi kidney transplant patients. 
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